Astria Therapeutics, Inc.

ATXSDelisted Jan 23, 2026

Industry: Pharmaceutical Preparations
SEC CIK: 0001454789

SEC filings (opens in a new tab)

Astria Therapeutics, Inc. was delisted on Jan 23, 2026; its insiders filed their last Form 4 on Jan 23, 2026; 141 institutions reported holding it in 13F filings for Q4 2025, worth $738.2M in total; Soros Fund Management was the only superinvestor holding it.

Key figures

Market cap: –; Not available
Insider buys: 0; Open market, last 90 days
Insider sells: 0; Open market, last 90 days
13F holders: 141; Q4 2025, +31 vs. previous quarter
13F value: $738.2M; Reported value at the end of Q4 2025
Superinvestors holding: 1; At the end of Q4 2025

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2024: –; No comparable prior period
Net income, FY2024: -$94.3M; No comparable prior period
Free cash flow, FY2024: -$81.5M; No comparable prior period
Revenue, Q3 FY2025: $706.0K; No comparable prior period

Short interest

See short data

From FINRA, settlement date Jan 15, 2026.

Short interest: 4.18M; Shares sold short
Change: −1.57M; −27.3% vs. previous
Days to cover: 5.78; At average daily volume

Superinvestors holding ATXS, Q4 2025

Go to the superinvestors tab

1 superinvestor reports holding Astria Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.

Soros Fund Management

George Soros

0.2%

Astria Therapeutics, Inc.'s share of the portfolio

Shares: 873,400
Value: $11.4M

Latest insider trades

See all insider trades

Open-market purchases and sales by Astria Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Apr 3, 2024 (view filing)	Apr 1	2 days	Morabito ChristopherChief Medical Officer	SSale	−10.0K	$13.59	−$135.9K	−100.0%0 after	10b5-1
Feb 5, 2024 (view filing)5:02 PM ET	Feb 1	4 days	Edelman Joseph and 3 othersDirector	PPurchase	+2.48M	$12.09	+$30.0M	+103.7%4.87M after
Jan 30, 2024 (view filing)	Jan 26-29	4 days	Morabito ChristopherChief Medical Officer	SSale	−10.0K	$11.14	−$111.4K	−100.0%0 after	2 lots10b5-1
Dec 22, 2023 (view filing)2:51 PM ET	Dec 21	1 day	Edelman Joseph and 3 othersDirector	PPurchase	+740.0K	$6.20	+$4.59M	+44.8%2.39M after
Oct 18, 2023 (view filing)4:11 PM ET	Oct 16	2 days	Edelman Joseph and 3 othersDirector	PPurchase	+1.07M	$6.51	+$7.00M	+200.1%1.61M after	2 lots
Oct 18, 2023 (view filing)4:11 PM ET	Oct 16	2 days	Edelman Joseph and 3 othersDirector	PPurchase	+2.42M	$7.86	+$19.0M	–345.4K after	Derivative4 lots
Dec 21, 2022 (view filing)4:52 PM ET	Dec 19	2 days	Edelman Joseph and 3 othersDirector	PPurchase	+908.3K	$11.01	+$10.0M	+698.4%1.04M after
Nov 23, 2021 (view filing)	Nov 19	4 days	Komjathy AndrewChief Commercial Officer	PPurchase	+100	$6.70	+$670	New position100 after

Top 10 13F holders, Q4 2025

See all 141 holders

The largest institutional positions in Astria Therapeutics, Inc. at the end of Q4 2025; share changes are against Q3 2025.

Institutions holding ATXS in Q4 2025
Institution	Shares	Value	% of portfolio	Change in shares	Action
Perceptive Advisors LLC	6,485,420	$84.9M	1.56%	00.0%	Unchanged
BlackRock, Inc.	3,832,755	$50.2M	0.00%	+344,553+9.9%	Added
Glazer Capital, LLC	3,776,154	$49.4M	1.30%	+3,776,154	New
Magnetar Financial LLC	3,431,007	$44.9M	0.44%	+3,431,007	New
Vanguard Group Inc	2,623,042	$34.3M	0.00%	−19,128−0.7%	Reduced
UBS Group AG	2,399,171	$31.4M	0.01%	+1,819,020+313.5%	Added
Deutsche Bank AG	1,762,802	$23.1M	0.01%	+1,729,463+5,187.5%	Added
Alliancebernstein L.P.	1,732,464	$22.7M	0.01%	+1,674,494+2,888.6%	Added
Balyasny Asset Management LLC	1,636,921	$21.4M	0.04%	+1,636,921	New
Geode Capital Management, LLC	1,073,766	$14.1M	0.00%	+115,522+12.1%	Added

Holders of 5% or more of ATXS

See all 1 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Astria Therapeutics, Inc..

Largest holders of ATXS from 13D and 13G filings
Holder	Latest form	Stake	Change	First filed	Latest filing	Filing
Glazer Capital, LLC	13G/A	6.61%3.78M shares	+1.08 ppfrom 5.53%	Dec 10, 20252 filings	Feb 12, 2026	SEC